Hall KS, et al. - Researchers examined the outcome after adjuvant doxorubicin and ifosfamide in a prospective non-randomized study based on a soft tissue sarcoma (STS) subject subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. Results revealed that median follow-up time for metastases-free survival was 3.9 years for the 150 eligible subjects. As per data, 5-year metastases-free survival was 70.4% and local recurrence rate was 14.0% in these patients. A benefit was seen with adjuvant chemotherapy, compared to similar historical control groups, in STS patients with defined poor prognostic factors. Patients in need of adjuvant chemotherapy could be identified by vascular invasion, tumor size, growth pattern and necrosis.